Sai Life Sciences FY26 Revenue up 29% to ₹2,192 Cr, PAT up 109% to ₹355 Cr
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 14 May 2026, 11:26 PM IST · BSE ID: a6b680fd-a28b-4078-b806-13dacd4e132a
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's annual revenue increased by 29% and its annual net profit more than doubled compared to last year.
🤖 AI Summary
- Sai Life Sciences reported FY26 Revenue from Operations of ₹2,192 Cr, a 29% increase over FY25.
- Full-year Net Profit (PAT) for FY26 stood at ₹355 Cr (before exceptional items), a 109% increase from FY25.
- EBITDA for FY26 increased by 56% to ₹661 Cr, with an EBITDA Margin of 30%.
- The company incurred Capex of ₹633 Cr during FY26, supporting expansion and technology investments.
- Growth attributed to deepening engagement with large pharma and momentum in integrated discovery services.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (FY26)
₹2,192 Cr
29%
EBITDA (FY26)
₹661 Cr
56%
Revenue from Operations (Q4FY26)
₹602 Cr
4%
PAT* (Q4FY26)
₹104 Cr
18%
🏢 How This Affects the Company
The company's revenue growth of 29% in FY26, driven by deeper engagement with large pharma and integrated discovery services, indicates an expansion of its market position within the CRDMO sector. Investments in new modalities and next-generation technologies support future capability expansion.
A 109% increase in PAT to ₹355 Cr and a 56% increase in EBITDA to ₹661 Cr demonstrate enhanced profitability and operational efficiency in FY26. The Capex of ₹633 Cr reflects significant investment in asset growth and capacity expansion.
Investments in new modalities and next-generation technologies suggest ongoing enhancements to the company's operational capabilities and service offerings. This includes expanding integrated CRDMO capabilities to meet evolving customer demand.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results press release.
👤
Who Is Affected
All shareholders are affected by the improved financial performance, as the company reported substantial increases in revenue, EBITDA, and net profit for FY26.
🔍
Management Signal
Management is focused on deepening customer relationships, expanding CRDMO capabilities, and disciplined capital allocation through significant Capex investments.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Review Q1 FY27 results — assess if revenue growth sustains above prior quarter.
Monitor future Capex disclosures — evaluate continued investment in expansion.
Follow earnings call transcript for management's detailed outlook and strategy.
LOW RISK
The filing reports strong financial performance with no immediate risks identified.
💡 Investor Takeaway
Sai Life Sciences reported FY26 Revenue from Operations at ₹2,192 Cr, a 29% increase from FY25. Net Profit (PAT) before exceptional items for FY26 rose by 109% to ₹355 Cr. EBITDA for FY26 grew 56% to ₹661 Cr. The company incurred ₹633 Cr in Capex during FY26.
⚖️ Strengths & Concerns
✅ Positives
- FY26 Net Profit (PAT) surged by 109% to ₹355 Cr (before exceptional items), indicating substantial profitability growth.
- Revenue from Operations increased by 29% year-on-year to ₹2,192 Cr in FY26, reflecting strong top-line expansion.
⚠️ Concerns
- Q4FY26 Revenue from Operations grew by 4% to ₹602 Cr compared to Q4FY25, a slower quarterly growth rate than the full-year average.
- While full-year PAT margin improved to 16%, it remained lower than the Q4FY26 PAT margin of 17%.
📅 Company Track Record
Sai Life Sciences FY26 net profit surged 96.86% to Rs. 3,414.81 million, as previously reported in filings on May 14, 2026. This press release provides additional details and context to those audited financial results.
Based on publicly available historical data. For context only.